Cambridge, U.K. – 01st September 2009

Read full press release here

Cambridge, U.K. – 07th April 2009
Amura reports antigen presentation study results

Read full press release here

Cambridge, U.K. – 07th April 2009
Amura announces positive results in chronic neuropathic pain model
Read full press release here

Cambridge, U.K. – 07th April 2009
Amura announces further positive results in a human breast cancer model of bone metastasis
Read full press release here

Cambridge, U.K. – 07th April 2009
Amura reports osteoarthritis study exceeded expected endpoints
Read full press release here

Cambridge, U.K. – 10th November 2008
Amura announces single-crystal XRD confirmation for key AMcore™ intermediate in its autoimmunity programme
Read full press release here

Cambridge, U.K. – 19th September 2008
Amura receives grant of WO02057270 in India
Amura announced its WO02057270 has been granted in India (No. 223705).  This provides further territorial protection to Amura’s AMcore™ intellectual property portfolio.

Cambridge, U.K. – 18th September 2008
Amura receives grant of WO02057270 in South Korea
Amura announced its WO02057270 has been granted in South Korea (No. 10-0860067).  This provides further territorial protection to Amura’s AMcore™ intellectual property portfolio.

Cambridge, U.K. – 16th September 2008
Amura receives grant of WO02057270 in the United States
Amura announced its WO02057270 has been granted in the United States (No. 7425562).  This provides further territorial protection to Amura’s AMcore™ intellectual property portfolio.

Cambridge, U.K. – 10th September 2008
Amura receives notice of acceptance of WO04007501 in the European Union
Amura announced its WO04007501 has been accepted in the European Union.  This patent now enters validation across individual European states providing provides further territorial protection to Amura’s AMcore™ intellectual property portfolio.

Cambridge, U.K. – 3rd September 2008
Amura receives notice of acceptance of WO02057270 in Indonesia
Amura announced its WO02057270 has been accepted in Indonesia.  This provides further territorial protection to Amura’s AMcore™ intellectual property portfolio.

Cambridge, U.K. – 21st August 2008
Amura receives notice of allowance of WO0232423 in Canada
Amura announced its WO0232423 has been accepted in Canada (No. 2425314).  This provides further territorial protection to Amura’s b-lactamase intellectual property portfolio.

Cambridge, U.K. – 20th August 2008
Amura receives grant of WO02057270 in the Russian Federation
Amura announced its WO02057270 has been granted in the Russian Federation (No. 2329266).  This provides further territorial protection to Amura’s AMcore™ intellectual property portfolio.

Cambridge, U.K. – 7th August 2008
Amura receives notice of acceptance of WO02057270 in Israel
Amura announced its WO02057270 has been accepted in Israel (No. 156774).  This provides further territorial protection to Amura’s AMcore™ intellectual property portfolio.

Cambridge, U.K. – 23rd July 2008
Amura receives grant of WO0232423 in the European Union
Amura announced its WO0232423 has been granted in the European Union (No. 1326607).  This patent now enters validation across individual European states providing further territorial protection to Amura’s b-lactamase intellectual property portfolio.

Cambridge, U.K. – 29th May 2008
Amura receives grant of WO02057270 in Australia
Amura announced its WO02057270 has been granted in Australia (No. 2002219397).  This provides further territorial protection to Amura’s AMcore™ intellectual property portfolio.

Cambridge, U.K. – 12th March 2008
Amura receives grant of WO0232423 in South Korea
Amura announced its WO0232423 has been granted in South Korea (No. 10-0814802).  This provides further territorial protection to Amura’s b-lactamase intellectual property portfolio.

Cambridge, U.K. – 7th March 2008
Amura receives grant of WO02057270 in the European Union
Amura announced its WO02057270 has been granted in the European Union (No. 136052).  This patent now enters validation across individual European states providing provides further territorial protection to Amura’s AMcore™ intellectual property portfolio.